OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: David Livingston

2 Projects | 1 Researchers | $13,750,000 Invested

2023

Metro International Biotech

David Livingston, PhD

Nicotinamide Mononucleotide in Patients with Alzheimer's Disease

  • Funding Amount: $10,750,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Mitochondria/Metabolic Function
  • Status: Active

2021

Metro International Biotech

David Livingston, PhD

MIB-626 FOR TREATMENT OF MILD DEMENTIA PATIENTS

  • Funding Amount: $3,000,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Mitochondria/Metabolic Function
  • Status: Active